Levels of lymphocyte-associated regulators of complement system CD55 and CD59 are changed in schizophrenia patients

References

• Abbas AK, Lichtman AH. 2009. Basic immunology: functions and disorders of the immune system. Philadelphia (PA): Saunders Elsevier.
   Google Scholar
• Addington D, Addington J, Maticka-Tyndale E. 1993. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry. 163(S22):39–44.
   Web of Science ®Google Scholar
• Ali FT, Abd El-Azeem EM, Hamed MA, Ali MAM, Abd Al-Kader NM, Hassan EA. 2017. Redox dysregulation, immuno- inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications. Schizophr Res. 188:98–109.
   PubMed Web of Science ®Google Scholar
• Aydemir Ö, Danacı Esen A, Deveci A, İçelli İ. 2000. The reliability and validity of the Turkish version of the Depression Scale in Calgary. Arch Neuropsychiatry. 37:82–86 (in Turkish).
   Google Scholar
• Cazzullo CL, Saresella M, Roda K, Calvo MG, Bertrando P, Doria S, Clerici M, Salvaggio A, Ferrante P. 1998. Increased levels of CD8+ and CD4 + 45RA + lymphocytes in schizophrenic patients. Schizophr Res. 31:49–55.
   PubMed Web of Science ®Google Scholar
• Christmas SE, De La Mata Espinosa CT, Halliday D, Buxton CA, Cummerson JA, Johnson PM. 2006. Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes. Immunology. 119(4):522–528.
   PubMed Web of Science ®Google Scholar
• De Witte L, Tomasik J, Schwarz E, Guest PC, Rahmoune H, Kahn RS, Bahn S. 2014. Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res. 154(1–3):23–29.
   PubMed Web of Science ®Google Scholar
• Drzyzga Ł, Obuchowicz E, Marcinowska A, Herman ZS. 2006. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 20(6):532–545.
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Cereser KM, Zortea K, Fries RG, Colpo GD, Moreeria L, Kapczinski F, Gama CS. 2010. Complement system in bipolar disorders and schizophrenia: C3 and C4. Bipolar Disord. 12:18–19.
   Web of Science ®Google Scholar
• Gurillo P, Jauhar S, Murray RM, MacCabe JH. 2015. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry. 2:725.
   Web of Science ®Google Scholar
• Hamann J, Wishaupt JO, Van Lier RAW, Smeets TJM, Breedveld FC, Tak PP. 1999. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum. 42(4):650–658.
   PubMedGoogle Scholar
• Howes OD, McCutcheon R. 2017. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry. 7(2):e1024–11.
   Google Scholar
• Huber-Lang M, Ekdahl KN, Wiegner R, Fromell K, Nilsson B. 2018. Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions. Semin Immunopathol. 40(1):87–102.
   PubMed Web of Science ®Google Scholar
• Idonije OB, Akinlade KS, Ihenyen O, Arinola OG. 2012. Complement factors in newly diagnosed Nigerian schizoprenic patients and those on antipsychotic therapy. Niger J Physiol Sci Publ Physiol Soc Niger. 27:19–21.
   PubMedGoogle Scholar
• Janeway CA, Jr, Travers P, Walport M, Shlomchik MJ. 2001. Immunobiology: The Immune System in Health and Disease: the major histocompatibility complex and its functions. New York (NY): Garland Science.
   Google Scholar
• Karpus ON, Kiener HP, Niederreiter B, Yilmaz-Elis AS ,van der Kaa J, Ramaglia V ,Arens R, Smolen JS ,Botto M, Tak PP, et al. 2015. CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis. Arthritis Res Ther. 17(1):1–12.
   PubMedGoogle Scholar
• Kawano M, Seya T, Koni I, Mabuchi H. 1999. Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 116(3):542–546.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Kew RR, Ghebrehiwet B, Janoff A. 1985. Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement. J Clin Invest. 5:1007.
   Google Scholar
• Kimberley FC, Sivasankar B, Paul Morgan B. 2007. Alternative roles for CD59. Mol Immunol. 44(1–3):73–81.
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Kihira Y, Kitamura S. 1988. Effects of cigarette smoking on blood levels of leukotrienes and plasma levels of complements C3A and C5A in healthy volunteers. Arch Environ Heal An Int J. 43:374.
   PubMedGoogle Scholar
• Konttinen YT, Čeponis A, Meri S, Vuorikoski A ,Kortekangas P ,Sorsa T ,Sukura A ,Santavirta S. 1996. Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis. 55(12):888–894.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang Q, Li N, Wang F ,Xiang H ,Zhang Z, Su Y, Huang Y, Zhang S, Zhao G, et al. 2016. Plasma levels of Th17-related cytokines and complement C3 correlated with aggressive behavior in patients with schizophrenia. Psychiatry Res. 246:700–706.
   PubMed Web of Science ®Google Scholar
• Li Q, Huang D, Nacion K, Bu H, Lin F. 2009. Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis. Mol Immunol. 46(15):2885–2891.
   PubMed Web of Science ®Google Scholar
• Li Z, Chen J, Yu H, He L, Xu Y, Zhang D, Yi Q, Li C, Li X, Shen J, et al. 2017. Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia. Nat Genet. 49(11):1576–1583.
   PubMed Web of Science ®Google Scholar
• Liu J, Miwa T, Hilliard B, Chen Y ,Lambris JD ,Wells AD ,Song WC. 2005. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med. 201(4):567–577.
   PubMed Web of Science ®Google Scholar
• Maes M, Delange J, Ranjan R, Meltzer HY ,Desnyder R ,Cooremans W ,Scharpé S. 1997. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 66:1–11.
   PubMed Web of Science ®Google Scholar
• Maino K, Gruber R, Riedel M, Seitz N, Schwarz M, Müller N. 2007. T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res. 152(2–3):173–180.
   PubMed Web of Science ®Google Scholar
• Mayilyan KR, Weinberger DR, Sim RB. 2009. The complement system in schizophrenia. Drug News Perspect. 21(4):200.
   Google Scholar
• Morera AL, Henry M, Garcia-Hernandez A, Fernandez-Lopez L. 2007. Acute phase proteins as biological markers of negative psycho-pathology in paranoid schizophrenia. Actas Esp Psiquiatr. 35:249–252.
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR. 1962. The Brief Psychiatric Rating Scale. Psychol Rep. 10(3):799–812.
   Web of Science ®Google Scholar
• Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V ,Ripke S, Carrera N, Legge SE, Bishop S, Cameron D, Hamshere ML, et al. 2018. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 50(3):381–389.
   PubMed Web of Science ®Google Scholar
• Pouget JG. 2018. The emerging immunogenetic architecture of schizophrenia. Schizophr Bull. 44(5):993–1004.
   PubMed Web of Science ®Google Scholar
• Presumey J, Bialas AR, Carroll MC. 2017. Complement system in neural synapse elimination in development and disease. In: Advances in immunology, 1st ed, Vol. 135. New York (NY): Elsevier Inc. p. 53–79.
   Google Scholar
• Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H ,Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H, et al. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 511(7510):421–427.
   PubMed Web of Science ®Google Scholar
• Robbins RA, Nelson KJ, Gossman GL, Koyama S, Rennard SI. 1991. Complement activation by cigarette smoke. Am J Phys. 260:259.
   Google Scholar
• Romeo B, Brunet-Lecomte M, Martelli C, Benyamina A. 2018. Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: a meta-analysis. Int J Neuropsychopharmacol. 21(9):828–836.
   PubMed Web of Science ®Google Scholar
• Sager RE, Walker AK, Middleton F, Robinson K, Webster MJ, Weickert CS. 2020. Trajectory of change in brain complement factors from neonatal to young adult humans. J Neurochem.157(3):479–493.
   PubMed Web of Science ®Google Scholar
• Sanders AR, Drigalenko EI, Duan J, Moy W, Freda J, Göring HHH, Gejman PV, on behalf of MGS. 2017. Transcriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis. Transl Psychiatry. 7(4):e1093–10.
   PubMedGoogle Scholar
• Sekar A, Bialas AR, De Rivera H, Davis A ,Hammond TR ,Kamitaki N ,Tooley K ,Presumey J ,Baum M ,Van Doren V, et al. 2016. Schizophrenia risk from complex variation of complement component 4. Nature. 530(7589):177–183.
   PubMed Web of Science ®Google Scholar
• Sória L. d S, Gubert C. d M, Ceresér KM, Gama CS, Kapczinski F. 2012. Increased serum levels of C3 and C4 in patients with schizophrenia compared to eutymic patients with bipolar disorder and healthy controls. Rev Bras Psiquiatr. 34(1):119–120.
   PubMed Web of Science ®Google Scholar
• Spivak B, Radwan M, Brandon J, Baruch Y, Stawski M, Tyano S, Weizman A. 1993. Reduced total complement haemolytic activity in schizophrenic patients. Psychol Med. 23:315–318.
   PubMed Web of Science ®Google Scholar
• Spivak B, Radwan M, Elimelech D, Baruch Y, Avidan G, Tyano S. 1989. A study of the complement system in psychiatric patients. Biol Psychiatry. 26:640–642.
   PubMed Web of Science ®Google Scholar
• Steiner J, Jacobs R, Panteli B, Brauner M, Schiltz K, Bahn S, Herberth M, Westphal S, Gos T, Walter M, et al. 2010. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin Neurosci. 260(7):509–518.
   PubMed Web of Science ®Google Scholar
• Stevens B, Allen NJ, Vazquez LE, Howell GR ,Christopherson KS ,Nouri N ,Micheva KD ,Mehalow AK, Huberman AD ,Stafford B, et al. 2007. The classical complement cascade mediates CNS synapse elimination. Cell. 131(6):1164–1178.
   PubMed Web of Science ®Google Scholar
• Sunyer J, Forastiere F, Pekkanen J, Plana E ,Kolz M ,Pistelli R ,Jacquemin B ,Brüske-Hohlfeld I ,Pitsavos CH ,Bellander T, et al. 2009. Interaction between smoking and the interleukin-6 gene affects systemic levels of inflammatory biomarkers. Nicotine Tob Res. 11:1353.
   Web of Science ®Google Scholar
• Tandon R, Keshavan M, Nasrallah H. 2008. Just the Facts” What we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 102(1–3):1–18.
   PubMed Web of Science ®Google Scholar
• Van Kesteren CFMG, Gremmels H, De Witte LD. 2017. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. Transl Psychiatry. 7(3): e1075–11.
   Google Scholar
• Wang M, Zhang L, Gage FH. 2019. Microglia, complement and schizophrenia. Nat Neurosci. 22(3):333–334.
   PubMed Web of Science ®Google Scholar
• Williams AS, Mizuno M, Richards PJ, Holt DS, Morgan BP. 2004. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum. 50(9):3035–3044.
   PubMedGoogle Scholar
• Wong C, Tsoi W, Saha N. 1996. Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res. 22(2):165–171.
   PubMed Web of Science ®Google Scholar
• Woo JJ, Pouget JG, Zai CC, Kennedy JL. 2020. The complement system in schizophrenia: where are we now and what’s next? Mol Psychiatry. 25(1):114–130.
   PubMed Web of Science ®Google Scholar